Convergent Therapeutics
PrivateLast Round
Series A
Extension
Sep 24, 2024
Est. Valuation
$277.8M
Total Funding Raised
$130M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Convergent Therapeutics is a biotechnology company developing next-generation targeted radiopharmaceutical therapies for the treatment of cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Convergent Therapeutics Comparables
Compare Convergent Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Blue Earth Therapeutics Ltd | 93% | |
| ARTBIO | 93% | |
| Full-Life Technologies | 89% | |
Convergent Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A Extension | Sep 24, 2024 | ||||
| Series A | May 3, 2023 |
Key People
Founding team and executive leadership
Convergent Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| RA Capital Management | Series A |
| OrbiMed | Series A |
| Invus Opportunities | Series A |
| Novo Holdings | Series A Extension |
| Invus | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Jul 2, 2026
Grew 26% QoQ, from 31 to 39 employees.
- Apr 30, 2026
Andrew Davis appointed Chief Business and Strategy Officer.
Convergent Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Convergent Therapeutics's valuation, stock price, and market status.